Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENSOR study of tumor organoid-guided targeted therapy in colorectal cancer and NSCLC
NL-OMON46891Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of axitinib, palbociclib, glasdegib, gedatolisib, gefitinib and 3 more in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (8 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall clinical response rate. Started Nov 2016; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON46891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46891.